Pharmacokinetic properties of anti-influenza neuraminidase inhibitors

Journal of Clinical Pharmacology

Volumn 53, Issue 2, 2013, Pages 119-139

  Chairat, Kalayanee ^a   Tarning, Joel ^a,b   White, Nicholas J ^a,b   Lindegardh, Niklas ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Influenza; Laninamivir; Neuraminidase inhibitors; Oseltamivir; Peramivir; Pharmacokinetics; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; PROBENECID; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESISTANCE; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG SENSITIVITY; DRUG URINE LEVEL; EXTRACELLULAR FLUID; HUMAN; IC 50; INFECTION PREVENTION; INFLUENZA; INFLUENZA A; INFLUENZA A (H5N1); INFLUENZA B; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STEADY STATE; TISSUE DISTRIBUTION;

ANIMALS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE;

EID: 84876964089     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270012440280     Document Type: Review

References (130)

1. Potter CW. A history of influenza. J Appl Microbiol . 2001 ; 91(4):572-579.
2. World Health Organization. Pandemic (H1N1) 2009-update 112. http://www.who.int/csr/don/2010-08-06/en/index.html
3. Burns A, van der Mensbrugghe, D, Timmer H. Evaluating the economic consequences of avian influenza. 2008. http://siteresources. worldbank.org/EXTAVIANFLU/Resources/EvaluatingAHIeconomics-2008.pdf
4. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol . 2008 ;3:499-522.
5. Fouchier RAM, Munster V, Wallensten A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol . 2005 ;79(5):2814-2822.
6. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Mol Biol Rev . 1992 ;56(1):152-179.
7. von Itzstein M, Thomson R. Anti-influenza drugs: the development of sialidase inhibitors. Handb Exp Pharmacol . 2009;(189):111-154.
8. Bouvier NM, Palese P. The biology of influenza viruses. Vaccine . 2008 ;26(suppl 4):D49-D53.
9. Bright RA, Medina M-j, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet . 2005 ;366(9492):1175-1181.
10. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis . 2009;48(suppl 1):S3-S13.
11. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med . 2009 ;361(23):2204-2207.
12. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis . 2010 ;10(9):621-629.
13. Zhang Y. Advances in the treatment of tuberculosis. Clin Pharmacol Ther . 2007 ;82(5):595-600.
14. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol . 2009 ;7(12):864-874.
15. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg . 2007;77(6)(suppl):181-192.
16. Kremsner PG, Krishna S. Antimalarial combinations. Lancet . 2004 ;364(9430):285-294.
17. Hofmann WP, Soriano V, Zeuzem S. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. In: Kr?sslich H-G, Bartenschlager R, eds. Antiviral Strategies . Vol 189. Berlin: Springer; 2009:321-346.
18. Tsibris AM, Hirsch MS. Antiretroviral therapy in the clinic. J Virol . 2010;84(11):5458-5464.
19. Widmer N, Meylan P, Ivanyuk A, Aouri M, Decosterd LA, Buclin T. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin Pharmacokinet . 2010;49(11):741-765.
20. Stubbs RJ, Harker AJ. Automated high-performance liquid chromatographic method for the determination of a neuraminidase inhibitor (GG167) in human serum by pre-column fluorescence derivatisation using benzoin. J Chromatogr B Biomed Appl . 1995 ;670(2):279-285.
21. Morris DM, Hussey BK, Geurin SL, Selinger KA. Determination of the novel sialic acid analog GG167 (GR121167X) in human urine by liquid chromatography: direct injection with column switching. J Pharm Biomed Anal . 1995 ;14(1-2):191-201.
22. Baughman TM, Wright WL, Hutton KA. Determination of zanamivir in rat and monkey plasma by positive ion hydrophilic interaction chromatography (HILIC)/tandem mass spectrometry. J Chromatogr . 2007 ;852(1-2):505-511.
23. Lindegardh N, Hanpithakpong W, Kamanikom B, et al. Quantification of the anti-influenza drug zanamivir in plasma using highthroughput HILIC-MS/MS. Bioanalysis . 2011 ;3(2):157-165.
24. Lindegardh N, Davies GR, Tran TH, et al. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob Agents Chemother . 2006 ;50(9):3197-3199.
25. Lindegardh N, Davies GR, Hien TT, et al. Importance of collection tube during clinical studies of oseltamivir. Antimicrob Agents Chemother . 2007 ;51(5):1835-1836.
26. Lindegardh N, Hanpithakpong W, Wattanagoon Y, Singhasivanon P, White NJ, Day NP. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J Chromatogr B . 2007 ;859(1):74-83.
27. Wiltshire H, Wiltshire B, Citron A, et al. Development of a highperformance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl . 2000 ;745(2):373-388.
28. Heinig K, Bucheli F. Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography-tandem mass spectrometry. J Chromatogr . 2008 ;876(1):129-136.
29. Bahrami G, Mohammadi B, Kiani A. Determination of oseltamivir carboxylic acid in human serum by solid phase extraction and high performance liquid chromatography with UV detection. J Chromatogr . 2008;864(1-2):38-42.
30. Lindegardh N, Hanpithakpong W, Phakdeeraj A, et al. Development and validation of a high-throughput zwitterionic hydrophilic interaction liquid chromatography solid-phase extraction-liquid chromatography-tandem mass spectrometry method for determination of the anti-influenza drug peramivir in plasma. J Chromatogr A . 2008 ;1215(1-2):145-151.
31. Li Y, Zhang X, Wang X, Li S, Ruan J, Zhang Z. Quantification of peramivir (a novel anti-influenza drug) in human plasma by hydrophilic interaction chromatography/tandem mass spectrometry. J Chromatogr . 2009 ;877(10):933-938.
32. Ishizuka H, Yoshiba S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol . 2010;50(11):1319-1329.
33. GlaxoSmithKline. Safety study to assess IV zanamivir for treatment of influenza infection in patients who are in hospital (NAI113678). http://clinicaltrials.gov/ct2/show/NCT01014988. Accessed February 11, 2011.
34. GlaxoSmithKline. A study of intravenous zanamivir versus oral oseltamivir in adults and adolecents hospitalized with influenza (ZORO). http://clinicaltrials.gov/ct2/show/NCT01231620. Accessed February 11, 2011.
35. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet . 1999;36(suppl 1):1-11.
36. Pukrittayakamee S, Jittamala P, Stepniewska K, et al. An openlabel cross-over study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. Antimicrob Agents Chemotherapy . 2011 ;55(9):4050-4057.
37. Cass LM, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet . 1999 ;36(suppl 1):21-31.
38. Bergstrom M, Cass LM, Valind S, et al. Deposition and disposition of [11C]zanamivir following administration as an intranasal spray: evaluation with positron emission tomography. Clin Pharmacokinet . 1999 ;36(suppl 1):33-39.
39. Peng AW, Milleri S, Stein DS. Direct measurement of the antiinfluenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother . 2000 ;44(7):1974-1976.
40. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother . 1999 ;43(7):1616-1620.
41. Peng AW, Hussey EK, Moore KH. A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. J Clin Pharmacol . 2000 ;40(3):242-249.
42. Dutkowski R, Smith JR, Davies BE. Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicrob Agents . 2010 ;35(5):461-467.
43. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet . 1999 ;37(6):471-484.
44. Wattanagoon Y, Stepniewska K, Lindegardh N, et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother . 2009 ;53(3):945-952.
45. Ogihara T, Kano T, Wagatsuma T, et al. Oseltamivir (tamiflu) is a substrate of peptide transporter 1. Drug Metab Dispos . 2009 ;37(8):1676-1681.
46. Morimoto K, Kishimura K, Nagami T, et al. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. J Pharm Sci . 2011 ;100(9):3854-3861.
47. Eisenberg EJ, Bidgood A, Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother . 1997 ;41(9):1949-1952.
48. Kurowski M, Oo C, Wiltshire H, Barrett J. Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses. Clin Drug Invest . 2004 ;24(1):49-53.
49. Morimoto K, Nakakariya M, Shirasaka Y, et al. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos . 2008;36(1):6-9.
50. Ose A, Ito M, Kusuhara H, et al. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos . 2009 ;37(2):315-321.
51. Ose A, Kusuhara H, Yamatsugu K, et al. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos . 2008 ;36(2):427-434.
52. Jhee SS, Yen M, Ereshefsky L, et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother . 2008 ;52(10):3687-3693.
53. Lee N, Wong CK, Chan PK, et al. Acute encephalopathy associated with influenza A infection in adults. Emerg Infect Dis . 2010 ;16(1):139-142.
54. Nakamura K, Schwartz BS, Lindegardh N, Keh C, Guglielmo BJ. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin Infect Dis . 2010 ;50(7):e47-e49.
55. Shi D, Yang J, Yang D, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther . 2006 ;319(3):1477-1484.
56. Zhu HJ, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos . 2009 ;37(2):264-267.
57. Hill G, Cihlar T, Oo C, et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos . 2002 ;30(1):13-19.
58. White NJ, Webster RG, Govorkova EA, Uyeki TM. What is the optimal therapy for patients with H5N1 influenza? PLoS Med . 2009;6(6):e1000091.
59. Bantia S, Parker CD, Ananth SL, et al. Comparison of the antiinfluenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother . 2001;45(4):1162-1167.
60. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother . 2010 ;54(11):4568-4574.
61. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B infection in high-risk patients. Int J Infect Dis . 2010 ;14(suppl 1):e85-e86.
62. Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther . 2005 ;10(8):901-910.
63. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res . 2006 ;69(1):39-45.
64. Centers for Disease Control and Prevention. Emergency use authorization of peramivir IV fact sheet for health care providers. http://www.cdc.gov/ h1n1flu/eua/pdf/final-hcp-fact-sheet-peramivirIV-CDC.pdf
65. Iyer GR, Liao S, Massarella J. Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers. AAPS PharmSci . 2002;4(4):E22.
66. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature . 2009 ;460(7258):1021-1025.
67. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother . 2009 ;53(1):186-192.
68. Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother . 2010 ;21(2):71-84.
69. Koyama K, Takahashi M, Oitate M, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother . 2009 ;53(11):4845-4851.
70. Koyama K, Takahashi M, Nakai N, et al. Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats. Xenobiotica . 2010 ;40(3):207-216.
71. Ishizuka H, Yoshiba S, Yoshihara K, Okabe H. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its prodrug, CS-8958. J Clin Pharmacol . 2011;51(2):243-251.
72. Daniel MJ, Barnett JM, Pearson BA. The low potential for drug interactions with zanamivir. Clin Pharmacokinet . 1999 ;36(suppl 1): 41-50.
73. Snell P, Oo C, Dorr A, Barrett J. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol . 2002 ;54(4):372-377.
74. Davies BE, Baldo PA, Lennon-Chrimes S, Brewster M. Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients. Br J Clin Pharmacol . 2010 ;70(6): 834-843.
75. Liu R, Tam TW, Mao J, et al. The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir. J Pharm Pharm Sci . 2010 ;13(1):43-55.
76. Oo C, Barrett J, Dorr A, Liu B, Ward P. Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin. Antimicrob Agents Chemother . 2002;46(6):1993-1995.
77. Butler D. Wartime tactic doubles power of scarce bird-flu drug. Nature . 2005;438(7064):6.
78. Howton JC. Probenecid with oseltamivir for human influenza A (H5N1) virus infection? N Engl J Med . 2006 ;354(8):879-880.
79. Morrison D, Roy S, Rayner C, et al. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS One . 2007;2(12):e1305.
80. Atiee G, Lasseter K, Baughman S, et al. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. J Clin Pharmacol . 2011 Sep 29 [Epub ahead of print]. doi:10.1177/0091270011414574.
81. Cass LM, Efthymiopoulos C, Marsh J, Bye A. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin Pharmacokinet . 1999 ;36(suppl 1):13-19.
82. Karie S, Launay-Vacher V, Janus N, Izzedine H, Deray G. Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Nephrol Dial Transplant . 2006 ;21(12):3606-3608.
83. Robson R, Buttimore A, Lynn K, Brewster M, Ward P. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant . 2006 ;21(9):2556-2562.
84. Arya V, Carter WW, Robertson SM. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir. Clin Pharmacol Ther . 2010 ;88(5):587-589.
85. Amy WP, Elizabeth KH, Bonnie R, Jeffrey LB. Pharmacokinetics and tolerability of a single inhaled dose of zanamivir in children. Curr Ther Res Clin Exp . 2000 ;61(1):36-46.
86. Oo C, Barrett J, Hill G, et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs . 2001 ;3(3):229-236.
87. Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol . 2003 ;59(5-6):411-415.
88. Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis . 2010;202(4):563-566.
89. Abdel-Rahman SM, Newland JG, Kearns GL. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr Drugs . 2011 ;13(1):19-31.
90. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med . 2003 ;349(12):1157-1167.
91. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol . 2000 ;40(8):836-843.
92. Abe M, Smith J, Urae A, Barrett J, Kinoshita H, Rayner CR. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann Pharmacother . 2006 ;40(10):1724-1730.
93. Worley KC, Roberts SW, Bawdon RE. The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Infect Dis Obstet Gynecol . 2008 ;2008:927574.
94. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet . 2005 ;44(10):989-1008.
95. Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol . 2006 ;2(6):947-960.
96. Dawes M, Chowienczyk PJ. Drugs in pregnancy: pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol . 2001 ;15(6):819-826.
97. Beigi RH, Han K, Venkataramanan R, et al. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol . 2011 ;204(6)(suppl 1):S84-S88.
98. Greer LG, Leff RD, Rogers VL, et al. Pharmacokinetics of oseltamivir in breast milk and maternal plasma. Am J Obstet Gynecol . 2011 ;204(6):524.e521- 524.e524.
99. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ . 2009 ;181(1-2):55-58.
100. Taylor WR, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS ONE . 2008;3(10):e3410.
101. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ . 2010 ;182(4):357-363.
102. Giraud C, Manceau S, Oualha M, et al. High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit. Antimicrob Agents Chemother . 2011 ;55(1):433-435.
103. Wildschut ED, de Hoog M, Ahsman MJ, Tibboel D, Osterhaus ADME, Fraaij PLA. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One . 2010;5(6):e10938.
104. Hter G, Zimmermann O, Maier L, et al. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis . 2010 ;50(9):1249-1251.
105. Nasu T, Ogawa D, Wada J, Makino H. Peramivir for severe influenza infection in a patient with diabetic nephropathy. Am J Respir Crit Care Med . 2010 ;182(9):1209-1210.
106. Snell P, Dave N, Wilson K, et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol . 2005 ;59(5):598-601.
107. Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis . 2011 ;52(3):301-312.
108. Smith AG, Sheridan PA, Harp JB, Beck MA. Diet-induced obese mice have increased mortality and altered immune responses when infected with influenza virus. J Nutr . 2007;137(5):1236-1243.
109. Karlsson EA, Beck MA. The burden of obesity on infectious disease. Exp Biol Med (Maywood) . 2010 ;235(12):1412-1424.
110. Karlsson EA, Sheridan PA, Beck MA. Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol . 2010;184(6):3127-3133.
111. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet . 2010 ;49(2):71-87.
112. Thorne-Humphrey LM, Goralski KB, Slayter KL, Hatchette TF, Johnston BL, McNeil SA. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). J Antimicrob Chemother . 2011;66(9): 2083-2091.
113. Pai MP, Lodise TP. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. AntimicrobAgents Chemother . 2011;55(12): 5640-5645.
114. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother . 2008 ;52(9):3284-3292.
115. Abed Y, Boivin G, Yoshida R, Kodama M, Hernandez JE. Parenteral peramivir treatment for oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses. J Infect Dis . 2011 ;204(10):1641-1642.
116. Tamura D, Sugaya N, Ozawa M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis . 2011;52(4):432-437.
117. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med . 2010 ;363(14):1381-1382.
118. Govorkova EA, Webster RG. Combination chemotherapy for influenza. Viruses . 2010 ;2(8):1510-1529.
119. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother . 2009 ;53(5):2120-2128.
120. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother . 2008 ;52(11):3889-3897.
121. Smee DF, Hurst BL, Wong MH, et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother . 2010;54(1):126-133.
122. Smee DF, Hurst BL, Wong MH, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res . 2010 ;88(1):38-44.
123. Bantia S, Kellogg D, Parker CD, Babu YS. Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. Antiviral Res . 2010;88(3):276-280.
124. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med . 2010;7(11):e1000362.
125. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One . 2010;5(2):e9332.
126. Brewster M, Smith JR, Dutkowski R, Robson R. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, openlabel study. Vaccine . 2006;24(44-46):6660-6663.
127. Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol . 2007 ;47(6):689-696.
128. Holodniy M, Penzak SR, Straight TM, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother . 2008 ;52(9):3013-3021.
129. Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol . 2008 ;48(8):935-947.
130. Yoshiba S, Okabe H, Ishizuka H. Pharmacokinetics of laninamivir after a single administration of its prodrug, laninamivir octanoate, a long-acting-neuraminidase inhibitor, using an easy-to-use inhaler in healthy volunteers. J Bioequiv Bioavailab . 2011;3:001-004.